Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | EGFR FPBMC |
Synonyms | |
Therapy Description |
EGFR FPBMC are autologous peripheral blood mononuclear cells armed with a bispecific antibody targeting EGFR and CD3, which potentially induce a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EGFR (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
EGFR FPBMC | EGFRBi Armed Fresh PBMC|autologous anti-CD3/EGFR bispecific antibody armed PBMCs | EGFR Immune Cell Therapy 5 | EGFR FPBMC are autologous peripheral blood mononuclear cells armed with a bispecific antibody targeting EGFR and CD3, which potentially induce a cytotoxic T-lymphocyte (CTL) response against tumor cells expressing EGFR (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06479239 | Phase Ib/II | EGFR FPBMC | Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer (Panc 002) | Recruiting | USA | 0 |